ArticleThe Indian journal of medical research2013
Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model.
Article in The Indian journal of medical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Transdermal Drug Delivery Systems: Different Generations and Dermatokinetic Assessment of Drug Concentration in Skin.Pharmaceutical medicine · 2024Review
- Azole Combinations and Multi-Targeting Drugs That Synergistically InhibitJournal of fungi (Basel, Switzerland) · 2024Review
- Antibiotic Loaded Phytosomes as a Way to Develop Innovative Lipid Formulations of Polyene Macrolides.Pharmaceutics · 2024Article
- The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses.Virulence · 2022Review
- Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications.Membranes · 2022Review
- In vitro and in silico analysis reveals antifungal activity and potential targets of curcumin on Paracoccidioides spp.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- Gallic and Ellagic Acids Are Promising Adjuvants to Conventional Amphotericin B for the Treatment of Cutaneous Leishmaniasis.Antimicrobial agents and chemotherapy · 2020Article
- Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.Pharmaceutics · 2020Review
- A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice againstNPJ vaccines · 2020Article
- Local delivery polymer provides sustained antifungal activity of amphotericin B with reduced cytotoxicity.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- Effective Tetradentate Compound Complexes againstMolecules (Basel, Switzerland) · 2018Article
- Novel Nanosized Chitosan-Betulinic Acid Against Resistant Leishmania Major and First Clinical Observation of such parasite in Kidney.Scientific reports · 2018Article
- Antileishmanial activity of a naphthoquinone derivate against promastigote and amastigote stages of Leishmania infantum and Leishmania amazonensis and its mechanism of action against L. amazonensis species.Parasitology research · 2018Article
- Marine Algae as Source of Novel Antileishmanial Drugs: A Review.Marine drugs · 2017Review
- Nanostructured delivery systems with improved leishmanicidal activity: a critical review.International journal of nanomedicine · 2017Review
- Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B.PloS one · 2017Article
- Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.BMC infectious diseases · 2015Article
- Leishmaniasis, malaria, and schistosomiasis concurrently in an 8-year-old boy.Saudi medical journal · 2015Article
- An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis.International journal of nanomedicine · 2014Article
- Amphotericin B-Loaded Extracellular Vesicles Derived fromIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectivesCurrent therapy for leishmaniasis is limited and unsatisfactory. Amphotericin B, a second-line treatment is gradually replacing antimonials, the first-line treatment and is used as the preferred treatments in some regions. Though, presently it is the only drug with highest cure rate, its use is severely restricted by its acute toxicity. In the present study novel lipid-amphotericin B formulations with lower toxicity than the parent drug were evaluated for the treatment of visceral leishmaniasis (VL) in a mouse model.
methodsThe toxicity and therapeutic efficacy of a new amphiphilic formulation of amphotericin B (Kalsome10) was compared to that of amphotericin B deoxycholate (Fungizone) in a mouse model of VL using quantitative real-time PCR (qRT-PCR).
resultsThe toxicity of amphotericin B was significantly less with liposomal formulation as compared to the deoxycholate form, evidenced by reduced nephrotoxicity and higher tolerated dose in BALB/c mice. The therapeutic efficacy was evaluated by quantitative real time (RT) PCR using primers highly specific for the ITS region of Leishmania donovani. There was reduction in parasite load by 2 log unit after 7 days of treatment and finally resulting in complete clearance of parasite from infected mice after 30 days of treatment with Kalsome10. INTERPRETATION &
conclusionsThis new formulation showed a favourable safety profile and better efficacy when compared to conventional amphotericin B. If production cost is kept low, it may prove to be a feasible alternative to conventional amphotericin B.
Indexed as
Identifiers
23703346PMC3724259W2141587987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.